Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.63 USD
Market Cap: 75.9m USD
Have any thoughts about
Aerovate Therapeutics Inc?
Write Note

Aerovate Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aerovate Therapeutics Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Aerovate Therapeutics Inc
NASDAQ:AVTE
Cash from Financing Activities
$46m
CAGR 3-Years
73%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1B
CAGR 3-Years
8%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Aerovate Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
46m USD

Based on the financial report for Dec 31, 2023, Aerovate Therapeutics Inc's Cash from Financing Activities amounts to 46m USD.

What is Aerovate Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
73%

Over the last year, the Cash from Financing Activities growth was 11 399%. The average annual Cash from Financing Activities growth rates for Aerovate Therapeutics Inc have been 73% over the past three years .

Back to Top